U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07350174) titled 'Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis' on Jan. 16.
Brief Summary: AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity. The current trial aims to assess the plasma and CSF PK, as well as the safety and tolerability of alpibectir and three doses of Eto in patients with newly diagnosed TBM. Additionally, we will investigate the effect of AlpE on the PK and efficacy of DTG during the first month of antiretroviral treatment (ART) for Human Immunodeficiency Virus (HIV)-positive patients.
Study Start ...